Study of NBI-1065890 for tardive dyskinesia in adults
Part of Brain & nervous system clinical trials.
This trial tests whether an oral medication, NBI-1065890, can reduce the involuntary muscle movements caused by long-term use of antipsychotic drugs. It is for adults with moderate to severe tardive dyskinesia who also have a stable mental health condition like schizophrenia or bipolar disorder.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with schizophrenia, schizoaffective disorder, bipolar disorder, or major depressive disorder for at least 3 months.
- You have tardive dyskinesia (uncontrollable muscle movements caused by antipsychotic medicines) for at least 3 months.
- Your dyskinesia is moderate to severe, as assessed by a doctor using a standardized rating scale.
- You do not have significant Parkinson-like symptoms, such as stiffness or tremors.
- You have not been hospitalized for your mental health condition in the last 6 months.
- You do not have a history of neuroleptic malignant syndrome (a rare, serious reaction to antipsychotic medication).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if valbenazine helps adults with tardive dyskinesia whose symptoms continue even after taking or stopping another similar medication. Tardive dyskinesia involves uncontrollable movements from long-term use of certain mental health drugs.
This study tests whether a non-invasive brain stimulation technique called repetitive transcranial magnetic stimulation (rTMS), targeted precisely using brain imaging, can safely reduce the involuntary movements caused by some psychiatric medications. If you have tardive dyskinesia, this treatment might help improve your motor symptoms.
This trial tests whether deutetrabenazine, a medication already used for tardive dyskinesia, can help people who also have intellectual or developmental disabilities. It aims to see if the drug reduces uncontrolled movements safely over 24 weeks.
This study looks at how people with tardive dyskinesia (a movement disorder) who have never been treated engage with their care. It aims to understand their patterns and experiences, which may help improve future treatment approaches.
This study tests a new medicine called NBI-1117568 for adults with schizophrenia over a longer period of time. Participants will stop their current antipsychotics and take this new drug to see how well it works and how safe it is.
This trial tests an investigational medicine called NBI-1117568 in adults with schizophrenia who are currently having a relapse or worsening of symptoms and need to stay in the hospital. The goal is to see if the medicine is safe and effective.
Hear when a new Tardive Dyskinesia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.